Skip to Content

Delcath Systems Inc DCTH

Morningstar Rating
$5.09 +0.48 (10.41%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

DCTH is trading at a 49% discount.
Price
$4.69
Fair Value
$6.93
Uncertainty
Extreme
1-Star Price
$556.28
5-Star Price
$1.93
Economic Moat
Vkbq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DCTH is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$4.61
Day Range
$4.515.15
52-Week Range
$2.257.99
Bid/Ask
$4.87 / $5.09
Market Cap
$116.68 Mil
Volume/Avg
50 / 217,510

Key Statistics

Price/Earnings (Normalized)
Price/Sales
40.01
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Value
Total Number of Employees
52

Comparables

Valuation

Metric
DCTH
NYKD
PCVX
Price/Earnings (Normalized)
Price/Book Value
7.343.045.27
Price/Sales
40.0132.31
Price/Cash Flow
Price/Earnings
DCTH
NYKD
PCVX

Financial Strength

Metric
DCTH
NYKD
PCVX
Quick Ratio
2.006.957.43
Current Ratio
2.266.957.54
Interest Coverage
−32.13
Quick Ratio
DCTH
NYKD
PCVX

Profitability

Metric
DCTH
NYKD
PCVX
Return on Assets (Normalized)
−101.25%−19.18%−21.69%
Return on Equity (Normalized)
−739.46%−26.31%−23.31%
Return on Invested Capital (Normalized)
−195.68%−30.96%−28.13%
Return on Assets
DCTH
NYKD
PCVX
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesNdftkfgbhNfyqqw$196.9 Bil
SYK
Stryker CorpZsqhlfrzwYsn$136.5 Bil
MDT
Medtronic PLCHwkssqxtyNkckdj$115.4 Bil
BSX
Boston Scientific CorpNvsjxjbdXlrmyy$100.9 Bil
EW
Edwards Lifesciences CorpZgszjjbnbTvbzl$57.3 Bil
DXCM
DexCom IncYtygdsknnvYwl$53.8 Bil
ZBH
Zimmer Biomet Holdings IncBsltzxnmjLfxpy$27.2 Bil
ALGN
Align Technology IncRjvpwvhrJnnlb$24.6 Bil
PHG
Koninklijke Philips NV ADRSmnzyfhnWhhgqy$18.4 Bil
PODD
Insulet CorpNhprjjmgKlqvkg$11.8 Bil

Sponsor Center